160 related articles for article (PubMed ID: 32401317)
1. Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies.
Frankel PH; Chung V; Tuscano J; Siddiqi T; Sampath S; Longmate J; Groshen S; Newman EM
JAMA Netw Open; 2020 May; 3(5):e204787. PubMed ID: 32401317
[TBL] [Abstract][Full Text] [Related]
2. A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.
Onar-Thomas A; Xiong Z
Contemp Clin Trials; 2010 May; 31(3):259-70. PubMed ID: 20298812
[TBL] [Abstract][Full Text] [Related]
3. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
4. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
5. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
Chen Z; Krailo MD; Sun J; Azen SP;
Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
7. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
8. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
9. Accelerated titration designs for phase I clinical trials in oncology.
Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
[TBL] [Abstract][Full Text] [Related]
10. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
11. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
Park M; Liu S; Yap TA; Yuan Y
JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of phase I cancer clinical trial designs.
Ahn C
Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
[TBL] [Abstract][Full Text] [Related]
14. Experimental designs for phase I and phase I/II dose-finding studies.
O'Quigley J; Zohar S
Br J Cancer; 2006 Mar; 94(5):609-13. PubMed ID: 16434987
[TBL] [Abstract][Full Text] [Related]
15. A statistical evaluation of dose expansion cohorts in phase I clinical trials.
Boonstra PS; Shen J; Taylor JM; Braun TM; Griffith KA; Daignault S; Kalemkerian GP; Lawrence TS; Schipper MJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710960
[TBL] [Abstract][Full Text] [Related]
16. Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
Iasonos A; O'Quigley J
J Clin Oncol; 2014 Aug; 32(23):2505-11. PubMed ID: 24982451
[TBL] [Abstract][Full Text] [Related]
17. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
Mick R; Ratain MJ
J Natl Cancer Inst; 1993 Feb; 85(3):217-23. PubMed ID: 8423626
[TBL] [Abstract][Full Text] [Related]
18. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
19. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
20. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]